Abstract:Myeloid-derived suppressor cells (MDSCs) are a hetero geneous group of cells, which can suppress the immune response, promote tumor progression and impair the efficacy of immunotherapies. Consequently, the pharmacological targeting of MDSC is emerging as a new immunotherapeutic strategy to stimulate the natural anti-tumor immune response and potentiate the efficacy of immunotherapies. Herein, we leveraged genetically modified models and a small molecule inhibitor to validate Calcium-Calmodulin Kinase Kinase 2 (CaMKK2) as a druggable target to control MDSC accumulation in tumor-bearing mice. The results indicated that deletion of CaMKK2 in the host attenuated the growth of engrafted tumor cells, and this phenomenon was associated with increased antitumor T cell response and decreased accumulation of MDSC. The adoptive transfer of MDSC was sufficient to restore the ability of the tumor to grow in Camkk2 -/- mice, confirming the key role of MDSC in the mechanism of tumor rejection. In vitro studies indicated that blocking of CaMKK2 is sufficient to impair the yield of MDSC. Surprisingly, MDSC generated from Camkk2 -/- bone marrow cells also showed a higher ability to terminally differentiate toward more immunogenic cell types (e.g inflammatory macrophages and dendritic cells) compared to wild type (WT). Higher intracellular levels of reactive oxygen species (ROS) accumulated in Camkk2 -/- MDSC, increasing their susceptibility to apoptosis and promoting their terminal differentiation toward more mature myeloid cells. Mechanistic studies indicated that AMP-activated protein kinase (AMPK), which is a known CaMKK2 proximal target controlling the oxidative stress response, fine-tunes ROS accumulation in MDSC. Accordingly, failure to activate the CaMKK2-AMPK axis can account for the elevated ROS levels in Camkk2 -/- MDSC. These results highlight CaMKK2 as an important regulator of the MDSC lifecycle, identifying this kinase as a new druggable target to restrain MDSC expansion and enhance the efficacy of anti-tumor immunotherapy.

Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction.

MEKK2 is Required for T-cell Receptor Signals in JNK Activation and Interleukin-2 Gene Expression.

MEKK2 and MEKK3 Orchestrate Multiple Signals to Regulate Hippo Pathway.

KMT2D Histone Methyltransferase Modulates Chromatin Accessibility During Regulatory T Cell Development (LYM6P.714)

Identification of Mekk2/3 Serine Phosphorylation Site Targeted by the Toll-Like Receptor and Stress Pathways

The MEKK1 PHD Ubiquitinates TAB1 to Activate MAPKs in Response to Cytokines.

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

Thymic Selection Can Compensate for Mutations Affecting T Cell Activation and Generate a Normal T Cell Repertoire in Mutant Mice

Conditional Deletion Of Shp2 Tyrosine Phosphatase In Thymocytes Suppresses Both Pre-Tcr And Tcr Signals

Tissue-specific modifier alleles determine Mertk loss-of-function traits

Disruption of the MAMP-Induced MEKK1-MKK1/MKK2-MPK4 Pathway Activates the TNL Immune Receptor SMN1/RPS6

Mip1, an MEKK2-Interacting Protein, Controls MEKK2 Dimerization and Activation

Lysine methyltransferase Kmt2d regulates naive CD8+ T cell activation-induced survival

MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver

Loss of MBD2 Affects Early T Cell Development by Inhibiting the WNT Signaling Pathway

A Cell-Intrinsic Role for Mst1 in Regulating Thymocyte Egress

CaMKK2 deletion increases antitumor potential through enhanced MHC-II expression in Macrophages

MEF2C regulates NK cell effector functions through control of lipid metabolism

A Sensitized Genetic System For The Analysis Of Murine B Lymphocyte Signal Transduction Pathways Dependent On Bruton'S Tyrosine Kinase

The MEKK1-MKK1/MKK2-MPK4 kinase cascade negatively regulates immunity mediated by a mitogen-activated protein kinase kinase kinase in Arabidopsis.

Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells